Allogene Therapeutics (ALLO) Interest Expenses (2018 - 2026)

Allogene Therapeutics has disclosed Interest Expenses across 4 years of filings, most recently posting $300000.0 for Q1 2026.

• Interest Expenses for Q1 2026 came in at $300000.0, up 100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 270.09% YoY), and the FY2025 annual result was $1.1 million, up 493.92% from the prior year.
• Interest Expenses came in at $300000.0 for Q1 2026 at Allogene Therapeutics, down from $313000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $344000.0 in Q3 2025 to a low of $81000.0 in Q4 2024.
• The 3-year median for Interest Expenses is $268000.0 (2025), against an average of $222285.7.
• Across the five-year window, Interest Expenses surged 286.42% in 2025 and surged 100.0% in 2026, its largest moves.
• Allogene Therapeutics' Interest Expenses stood at $81000.0 in 2024, then soared by 286.42% to $313000.0 in 2025, then dropped by 4.15% to $300000.0 in 2026.
• The last three Interest Expenses figures came in at $300000.0 (Q1 2026), $313000.0 (Q4 2025), and $344000.0 (Q3 2025), per Business Quant data.